Phase 1b study of RGX-202-01, a first-in-class oral inhibitor of the SLC6A8/CKB pathway, in combination with FOLFIRI and bevacizumab (BEV) in second-line advanced colorectal cancer (CRC) Meeting Abstract
| Authors: | Hendifar, A.; Rosen, L.; McRee, A.; Cercek, A.; Basu-Mallick, A.; Spigel, D.; Tavazoie, S.; Rowinsky, E.; Szarek, M.; Gonsalves, F.; Kurth, I.; Andreu, C.; Busby, R.; Spector, S.; Darst, D.; Lebaka, N.; Bechar, N.; Tavazoie, M.; Wasserman, R.; Fakih, M. |
| Abstract Title: | Phase 1b study of RGX-202-01, a first-in-class oral inhibitor of the SLC6A8/CKB pathway, in combination with FOLFIRI and bevacizumab (BEV) in second-line advanced colorectal cancer (CRC) |
| Meeting Title: | ESMO 24th World Congress on Gastrointestinal Cancer 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2022 Jun 29-Jul 2 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-06-01 |
| Start Page: | S294 |
| Language: | English |
| ACCESSION: | WOS:000823826500138 |
| DOI: | 10.1016/j.annonc.2022.04.215 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: P-125 -- Source: Wos |
